Status:
COMPLETED
Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is an interventional mono-centric study in patients with BRAF mutated metastatic melanoma treated with BRAF/MEK inhibitors. The aim of the study is to test the grafting of patient tumoral cells i...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years
- Signed written informed consent
- Patient with BRAF V600 mutated metastatic or unresectable melanoma histologically confirmed
- BRAFi/MEKi treatment indication
- Patient with skin tumor (excluded face and skinfold) available for biopsy
- Measurable disease as defined by RECIST v1.1 criteria
- Patient affiliated to or a beneficiary of a social security category
Exclusion
- Ocular melanoma
- Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study
- Pregnant or nursing (lactating) women
- Patients protected by law
Key Trial Info
Start Date :
April 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04039672
Start Date
April 2 2021
End Date
July 2 2024
Last Update
October 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Dermatologie, Centre hospitalier Lyon Sud, HCL
Pierre-Bénite, France, 69495